抗病毒治疗对失代偿期乙型肝炎肝硬化的疗效研究
Research on the efficacy of antiviral therapy for hepatitis B with decompensated cirrhosis
于晓燕 1龚君佐 2任崇松 1岳爽 1梁建英1
作者信息
- 1. 南充市中心医院感染科 四川南充 637000
- 2. 川北医学院附属医院 637000
- 折叠
摘要
目的：探讨抗病毒治疗对失代偿期乙型肝炎肝硬化患者临床效果及对病程进展的影响。方法：77例失代偿期乙型肝炎肝硬化患者随机分成治疗组（39例）和对照组（38例），治疗组服用阿德福韦酯10m g/d进行抗病毒治疗，同时给予常规综合护肝对症治疗；对照组仅给予常规综合护肝对症治疗，随访时间为（36士3）个月。结果：两组死亡率分别为7.7%和15.7%(P<0.05)，肝癌发生率分别为2.6%和2.6%(P>0.05)。治疗后child-Pugh评分下降>2分的患者比率分别为89.2%和62.4%(P<0.05)，HBV-DNA转阴率分别为84.6%和13.2%(P<0.01)。结论：对失代偿期肝硬化患者进行抗病毒治疗可以抑制乙肝病毒复制，肝功能得到改善，可延缓病情进展，延长患者生命。
Abstract
Objective: To investigate the clinical effect and impact on progression in patients with anti-viral therapy for decompensated cirrhosis . Methods: 77 cases of decompensated cirrhosis patients were randomly divided into treatment group (39 cases) and control group (38 cases), the treatment group taking adefovir dipivoxil 10mg / d for anti-viral treatment, while giving the routine liver symptomatic treatment; control group were given the routine liver symptomatic treatment, folow-up time was (36 ± 3) months. Results: Two mortality rates were 7.7% and 15.7% (P <0.05), liver cancer incidence was 2.6% and 2.6% (P > 0.05). After treatment, child-Pugh score decreased> 2 points patient ratios were 89.2% and 62.4% (P <0.05), HBV-DNA negative rates were84.6% and 13.2% (P <0.01).Conclusion: Patients with decompensated cirrhosis antiretroviral therapy can suppress HBV replication, liver function improved, can delay disease progression and prolong the lives of patients.
关键词
抗病毒治疗/失代偿期/乙型肝炎肝硬化/阿德福韦酯Key words
Antiretroviral/therapy decompensated/liver cirrhosis/adefovir dipivoxil引用本文复制引用
出版年
2014
NETL
NSTL
万方数据